Diabetes mellitus is a common chronic condition and an old friend to family physicians practising in the community. The long-standing practice had aimed to lower glucose levels in type 2 diabetes to prevent long-term complications. The recent evidence from some publications since June 2008 had suggested the possible harm to our patients when we adopt intensive treatment strategies with tight treatment control targets (below HbA1c of 6%) and many meta-analyses have been published. This review highlights the evidence from recent studies that shook the previous dogma and the new clinical equipoise.
INTrODUCTION
Type 2 diabetes mellitus' prevalence is increasing worldwide and according to our latest National Health Survey conducted in 2010, our local diabetes prevalence rate has gone up to 11.3%, up from 9% in 2004 1 . The rise is across all ages, genders and ethnic groups. This chronic disease and its long-term complications is potentially a huge burden to our healthcare system. Knowing the current evidence shaping the ideal blood glucose control target in various guidelines and recommendations will help physicians decide what is the best for the patients that walks into our consultation rooms.
Previously our knowledge in diabetes mellitus was derived from epidemiology observational studies 2 which showed the continuous relationship between glycaemic control and risk of complications. This had shown that lower glycaemic control led to improved outcomes, especially with microvascular (renal and retinal) complications.
Approximately a decade later in June 2008, the treatment targets were challenged when the ACCORD (Action to Control Cardiovascular Risk in Diabetes) study group published its interim analysis suggesting that tight blood glucose control treatment strategies could actually be harmful 3 . Following that publication, other studies involving tight glucose targets and secondary analyses have also been published around the same topic.
This review aims to highlight the important findings and evidence that supported this new clinical equipoise. with abstracts in the English language were screened. In addition, a hand search for established and recent studies involving tight glucose control in the treatment of other diabetes mellitus was conducted. Studies which only focused on specific treatment modalities or involved a combination of conditions, e.g. hypertension or stroke, were excluded from this review. The Jadad score of 3 or more was used to select articles with study designs of a high quality 4 . Randomised controlled trials with a score of 3 or more were included. Five randomised control trials, one cohort study and 3 secondary analyses were selected for this review.
METhODs

A search for studies through Medline and the
rEsUlTs
Action to Control Cardiovascular risk in Diabetes (ACCOrD) 3
The ACCORD study was an open randomised trial with a Jadad score of 3. The group planned to test the benefits of glycaemic control in a 2 by 2 factorial study design, and had specific exclusion criteria for patients that were unsuitable for tight control, such as patients at high risk of hypoglycaemic events. Their 10,251 participants (average age 62 years), who were recruited from multiple centres in the United States of America and Canada, with either a history of cardiovascular disease (CVD) or a significant CVD risk were randomised to either the tight glucose target (with target glycated haemoglobin levels (HbA1c) below 6.0) or standard glucose target (with target HbA1c between 7 and 7.9%). At 1 year, the median HbA1c levels of 6.4% and 7.5% were achieved in the tight glucose target group and the standard target group respectively. The ACCORD study group had raised the alarms of a possible unrecognised risk to treating diabetic patients to a tight control target. The interim data analysis, after a mean of 3.5 years, found more all-cause deaths in the tight-control arm of the study than the standard-treatment group. These results were consistent even with stratification by previous cardiovascular events or multiple cardiovascular risk factors. The higher rate of all-cause deaths may be due to factors associated with the various strategies employed to achieve the tight control. Further analyses by the group of these factors did not isolate any conclusive reason for the excess number of deaths.
ADVANCE 5
The ADVANCE study was also an open randomised trial with a Jadad score of 3. Their 11,140 participants (average age of 66 years), were recruited from multiple sites from Europe, Australia, New Zealand, Canada and Asia, and were randomised to a tight glucose control (with HbA1c ≤6.5%) arm and a standard control arm (according to "local guidelines"). The primary therapy for the tight control arm included the sulphonylurea gliclazide (modified release) and additional medications and the standard control included any medications but gliclazide (modified release). The ADVANCE study group released their interim analysis results a week after ACCORD's publication (2008) showing tight glucose control strategies yielded a 10% relative reduction in the combined outcome of major macrovascular and microvascular events. There was a significant 21% relative rate reduction in renal complications. They also analysed their results to address the findings of increased deaths by the ACCORD study and presented no significant effects of the type of glucose control on both deaths from cardiovascular causes and deaths from any cause. 6 In 2009, the Veterans Affairs Diabetes Trial (VADT) study group also published their findings for 1,791 participants (average age of 60 years old) in the same journal. In the VADT study, the goal for the tight control group was an absolute HbA1c reduction of 1.5% as compared with the standard therapy group. At the end of the study, the median HbA1c were 6.9% in the tight control group and 8.4% in the standard therapy group. They did not find a significant difference in the reduction of microvascular or macrovascular complications and no significant increase in mortality in their tight glucose control group. The VADT study had a Jadad score of 3. 7 The UKPDS (Glucose Control) study showed that intensive glucose therapy (with median HbA1c of 7.0%) in newly diagnosed participants with type 2 diabetes (with sulphonylurea or insulin or metformin in obese patients) led to lower microvascular complications compared with conventional treatment (with median HbA1c of 7.9%). The follow-up analysis after 10 years revealed that the intensively controlled group had less microvascular complications (risk reduction of 25%) and macrovascular complications (risk reduction of 16% for combined fatal or non-fatal myocardial infarction and sudden death, p=0.052) despite the lack of sustained difference in HbA1c levels after 10 years. Secondary analyses did not show any glycaemic threshold in relation to risk of microvascular complications. This risk also extended into the normal glycaemia range of HbA1c. 8 As type 2 diabetes mellitus is often part of the metabolic syndrome which is difficult to separately account for the individual contributory risk of developing cardiovascular events and mortality, the DCCT Research Group for Type 1 Diabetes published evidence to support the benefits of tight glycaemic control (with mean HbA1c of 7.0%) to near physiological levels (with target HbA1c of <6.1%) to reduce the rate of microvascular (risk reduction of 57%) complications. The DCCT-Epidemiology of Diabetes Interventions and Complications (EDIC) 9 required 9 years of follow-up to show that participants previously randomised to the intensive arm had a reduction in CVD outcomes (risk reduction of 42%, p=0.02) and risk of non-fatal myocardial infarction (MI), stroke, or CVD death (risk reduction of 57%, p=0.02) compared with those previously in the standard arm.
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This level of evidence is difficult to demonstrate in type 2 diabetes mellitus populations, where other risk factors are highly prevalent and intensive glycaemic control is often the most difficult to achieve in multi-factorial intervention trials for CVD endpoints 10 . The additive benefit of glycaemia control can only be tested with either a very large study population or a very long duration of follow-up. study by Craig et al 11 A large retrospective cohort study on type 2 diabetes mellitus patients, above 50 years old in the United Kingdom, was published in Lancet. They had 27,965 patients on oral treatment and 20,005 patients on insulin and were monitored over time for their all-cause mortality. They found that compared with the HbA1c decile with the lowest hazard (median HbA1c 7.5%, IQR 7.5-7.6%), the adjusted hazard ratio (HR) of all-cause mortality in the lowest HbA1c decile (6.4%, 6.1-6.6) was 1.52 (95% CI 1.32-1.76), and in the highest HbA1c decile (median 10.5%, IQR 10.1-11.2%) was 1.79 (95% CI 1.56-2.06). These supported a general U-shaped association, with the lowest HR at an HbA1c of about 7.5%. HR for all-cause mortality was 1.49 (95% CI 1.39-1.59) in people given insulinbased regimens compared to oral therapy. They proposed for future studies to aim to define the minimum HbA1c value that has the lowest HR for all cause mortality in treated diabetic patients.
secondary Analyses 12-14
There were 3 secondary analysis of tight glucose control on CVD outcomes published in the year 2009. They concluded separately that tight glucose control reduced the relative risk for CVD complications by 0.9 (with 95% CI, 0.83-0.99), primarily from a 15% reduction in risk of myocardial infarction (HR 0.85, 95% CI, 0.76-0.94). There was no significant change in events of stroke, CVD death and all-cause mortality. Two of the analyses concluded that patients under the tight glucose treatment regimes were more than 2 times likely to experience a severe hypoglycaemic event.
DIsCUssION
Type 2 diabetes mellitus is an old condition that many of us were comfortably managing in the past. Recent studies, which focused on tight glucose control strategies, had produced evidence that were in contrast to many epidemiological studies. The most important confounder is in the time period these observations were made. Recent advances in treatment of other cardiovascular risk factors in type 2 diabetic patients such as the use of statin therapy, intensive blood pressure control and aspirin therapy had dramatically reduced the CVD complications risk, making it very difficult to prove the remaining effect of tight glucose control.
There are currently many post-hoc and secondary analyses on the studies presented. Among them, the 5 main differences between the tight glucose control arm of ACCORD as compared to ADVANCE and VADT were: (i) the overall magnitude in the reduction in HbA1c; (ii) the speed of reduction in HbA1c within the first 4 months (with reduction of approximately 1.4% in the intensive therapy group and 0.6% in the standard therapy group); (iii) the difference in drug regimes in the intensive arm, although the further sub-analyses were unable to attribute the increased rates of deaths to any single drug or drug class; (iv) the observed rates of hypoglycaemic events; and (v) the postulated adverse drug interactions among the various drug classes at higher doses.
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These have led to many interim clinical practice recommendations to be cautious about management strategies that involve glucose levels dropping "too fast" and "too much". This is an important consideration when formulating our treatment plans and titrating the regime of hypoglycaemic medication or insulin therapy. The counterbalancing evidence from the UKPDS 10-year follow-up was that "initial intensive glucose control" at the point of diagnosis, despite the lack of sustained differences after the completion of the trial, continued to show benefits 10 years later. There is, however, no conclusive answer for "how fast is too fast?".
Other important considerations for clinicians are to pay particular attention to risk of severe hypoglycaemic events and to be vigilant with possible drug interactions among high-dosed drugs when adopting any intensive multifactorial risk intervention approach. Any observed suspicion should be actively reported for further confirmations.
The current evidence compels us to review all patients with type 2 diabetes mellitus with HbA1c control below 6.0% for macro-and microvascular risk. Those with HbA1c lower than 6.0% targets have been observed in normal physiological levels and the tight control arm of the DCCT trial to demonstrate long-term protection and benefits. Patients not treated pharmacologically should be complimented on their diet and lifestyle measures. If treated with medications, existing complications, such as nephropathy, may support the benefits of continued tight glucose control targets. The uncertainty about the increased rates of all-cause mortality3,11 should be communicated to these patients and before making an informed decision, with the patient, to keep this treatment target. There are many other recommendations published as more post-hoc and secondary analyses race to identify the correct sub-population suitable for the different glucose targets, but the bottom line conclusion is the need to be updated on the latest evidence and individualise the ideal target for every individual type 2 diabetic patient.
CONClUsION
Judging from the number of new publications surrounding this topic, any clinician or patient can be easily confused by the many conclusions drawn. The one safe conclusion is that there is indeed a new clinical equipoise. We should all be familiar with the findings of these important studies, continue to be updated on emerging evidence and individualise the HbA1c target for each of our own patients with type 2 diabetes.
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